Acetylisovaleryltylosin tartrate formulation preparation method and prepared acetylisovaleryltylosin tartrate formulation thereof, and pharmaceutical composition

A technology of tivalamectin and composition, which is applied in the field of veterinary drugs, can solve the problems of poor curative effect and low bioavailability of drugs, and achieve the effects of improving clinical treatment effect, delaying release, and prolonging action time

Active Publication Date: 2015-11-11
LUOYANG HUIDE BIO ENG CO LTD
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] At present, most of the common tivalamectin premixes and soluble powders are on the market. Because the preparation process is relatively simple, and it is easily affected by gastric acid, the bioavailability of the drug is low, resulting in poor curative effect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Acetylisovaleryltylosin tartrate formulation preparation method and prepared acetylisovaleryltylosin tartrate formulation thereof, and pharmaceutical composition
  • Acetylisovaleryltylosin tartrate formulation preparation method and prepared acetylisovaleryltylosin tartrate formulation thereof, and pharmaceutical composition
  • Acetylisovaleryltylosin tartrate formulation preparation method and prepared acetylisovaleryltylosin tartrate formulation thereof, and pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] The preparation of embodiment 1 tivalamectin preparation of the present invention:

[0030] This example aims to prepare a tyvalancin preparation, including a core material and a wall material, the core material is 100-1000 μm tyvalancin particles in size, the wall material is polylactic acid and gum arabic, the ratio 1:1.

[0031] The preparation method of the tyvanectin preparation comprises the steps of:

[0032] 1. Weigh polylactic acid (molecular weight 5000) and gum arabic wall material and water according to the ratio of 0.05:1 in the ratio of 1:1, dissolve in water, and prepare an adhesive solution;

[0033] 2. Weigh the core material and binder solution according to the ratio of 0.4:1, mix them homogeneously to make a mixture, spray the mixture to dry, the air inlet temperature is 150°C, the outlet air temperature is 60°C, cool , that is, tyvalancin preparations.

Embodiment 2

[0034] The preparation of embodiment 2 tivalamectin preparations of the present invention:

[0035] The purpose of this example is to prepare a kind of tivalamectin preparation, including a core material and a wall material. Gum Arabic in a 1:1 ratio.

[0036] The preparation method of the tyvanectin preparation comprises the steps of:

[0037] 1. Weigh the polylactic acid, gum arabic wall material and water according to the ratio of 0.10:1 in the ratio of 1:1, add it into water to dissolve, and prepare an adhesive solution;

[0038] 2. Weigh the core material and the binder solution according to the ratio of 0.6:1, mix them homogeneously to make a mixture, and spray the mixture to dry (the air inlet temperature is 160°C, and the air outlet temperature is 70°C), After cooling, the tyvalancin preparation is obtained.

Embodiment 3

[0039] The preparation of embodiment 3 tyvanectin preparations of the present invention:

[0040] The purpose of this example is to prepare a tyvalactin preparation, which includes a core material and a wall material, the core material is 100-1000 μm tyvalancin particles in size, the wall material is polylactic acid (molecular weight 30000) and Gum Arabic in a 1:1 ratio.

[0041] The preparation method of the tyvanectin preparation comprises the steps of:

[0042]1. Weigh the polylactic acid, gum arabic wall material and water according to the ratio of 0.10:1 in the ratio of 1:1, add it into water to dissolve, and prepare an adhesive solution;

[0043] 2. Weigh the core material and the binder solution according to the ratio of 0.7:1, mix them homogeneously to make a mixture, and spray the mixture to dry (the air inlet temperature is 170°C, and the air outlet temperature is 80°C), After cooling, the tyvalancin preparation is obtained.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Molecular weightaaaaaaaaaa
Molecular weightaaaaaaaaaa
Login to view more

Abstract

The present invention provides an acetylisovaleryltylosin tartrate formulation preparation method, which comprises: (1) adding a wall material to water, and dissolving to prepare a binder solution, wherein the wall material comprises polylactic acid and arabic gum according to a ratio of 1:1; (2) adding an acetylisovaleryltylosin tartrate core material to the binder solution, and uniformly mixing to prepare a mixture; and (3) carrying out spray drying of the mixture prepared in the step (2) to prepare the acetylisovaleryltylosin tartrate formulation. According to the present invention, the acetylisovaleryltylosin tartrate formulation prepared through the method is stable and lastly act, and the cure rate is extremely high when the composition comprising the acetylisovaleryltylosin tartrate formulation and doxycycline is used to treat swine mycoplasma pneumonia.

Description

technical field [0001] The invention belongs to the field of veterinary drugs, and in particular relates to a preparation of tivalamectin, a preparation method thereof and a composition containing the preparation of tivalamectin. Background technique [0002] Mycoplasma suis pneumonia is a direct contact and chronic respiratory infectious disease caused by Mycoplasma hyopneumoniae. The disease has a high incidence and is widely prevalent in the world. Once it is introduced into the pig farm, it is difficult to eradicate it and has become a chronic disease in pig farms. . The current intensive breeding makes the disease easier to spread and spread, causing huge economic losses to the pig industry. [0003] The main symptoms are cough and wheezing, and the lesion is characterized by "meat-like" or "shrimp-like" consolidation of the apical lobe, heart lobe, middle lobe, and front edge of the diaphragm, and hilar lymph node enlargement. Pigs of different breeds, ages, and sexe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61P31/04A61K31/65
Inventor 梁立钦于利红李冬冬高富红
Owner LUOYANG HUIDE BIO ENG CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap